Codiak BioSciences Inc (CDAK)
$0.01
$0.00
(-25.62%)
As on 07-Jun-2023 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$34 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-17 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.3
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
36,829,600
5 Years Aggregate
CFO
$-193.66 Mln
EBITDA
$-268.79 Mln
Net Profit
$-210.30 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Codiak BioSciences Inc (CDAK)
| -97.7 | -25.0 | -98.4 | -99.6 | -- | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Codiak BioSciences Inc (CDAK)
| -96.4 | -65.5 |
|
BSE Sensex
| 4.4 | 22.0 |
|
BSE Sensex
| 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Codiak BioSciences Inc (CDAK)
|
0.0 | 2.8 | 33.6 | -29.2 | -158.8 | -67 | -- | 0.5 |
| 84.9 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 72.1 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.4 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 351.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 533.8 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 600.7 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 344.8 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Codiak BioSciences Inc (CDAK)
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead... product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. On March 27, 2023, Codiak BioSciences, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Pres, CEO & Director
Dr. Douglas Edward Williams Ph.D.
-
Pres, CEO & Director
Dr. Douglas Edward Williams Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Codiak BioSciences Inc (CDAK)
What is the current share price of Codiak BioSciences Inc (CDAK) Today?
The share price of Codiak BioSciences Inc (CDAK) is $0.01 (NASDAQ) as of 07-Jun-2023 09:30 EDT. Codiak BioSciences Inc (CDAK) has given a return of -99.6% in the last 1 years.
What is the current PB & PE ratio of Codiak BioSciences Inc (CDAK)?
Since, TTM earnings of Codiak BioSciences Inc (CDAK) is negative, P/E ratio is not available.
The P/B ratio of Codiak BioSciences Inc (CDAK) is 0.55 times as on 07-Jun-2023, a 90 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
What is the 52 Week High and Low of Codiak BioSciences Inc (CDAK)?
The 52-week high and low of Codiak BioSciences Inc (CDAK) are Rs -- and Rs -- as of 30-Aug-2026.
What is the market cap of Codiak BioSciences Inc (CDAK)?
Codiak BioSciences Inc (CDAK) has a market capitalisation of $ 3 Mln as on 07-Jun-2023. As per SEBI classification, it is a company.
Should I invest in Codiak BioSciences Inc (CDAK)?
Before investing in Codiak BioSciences Inc (CDAK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.